The HARMONY Alliance is a public-private partnership of more than 80 organizations (53 Partners and 35 Associated Members) funded by the Innovative Medicines Initiative for a period of 5 years (2017-2021). Myeloma Patients Europe (MPE) is part of the HARMONY Patient Cluster which is a unique group of 7 European Patient Umbrella Organizations working in the different areas of hematological diseases within the HARMONY Alliance.
The HARMONY Big Data Platform is one of the largest of its kind in the world and the team is aiming to expand it to at least 100,000 patients during the lifetime of the HARMONY Alliance. During the European Hematology Association (EHA) Annual Meeting, that was held from 13 to 16 June in Amsterdam, The Netherlands, HARMONY announced that its innovative Big Data Platform has reached an important milestone capturing anonymized data records from 45,000 patients with blood cancers.
“To answer the key outstanding questions in the field of hematology, we need harmonized and high-quality data on treatment outcomes in thousands of patients which today are contained in multiple clinical trials and registries”, says Mario Boccadoro, University of Turin, Leadership of the HARMONY Research Project on Multiple Myeloma. “HARMONY has developed technical and organizational procedures to overcome these obstacles, allowing the alliance to assemble anonymized data records from thousands of European patients into one harmonized Big Data Platform.”
HARMONY researchers are already mining the Big Data Platform to address pressing research questions such as: Does one specific treatment provide improved outcomes in patients with aggressive Multiple Myeloma?; Which subgroups of Myelodysplastic Syndromes patients benefit from treatment with hypomethylating agents? What are the most important outcomes for Acute Myeloid Leukemia, according to patients, clinicians, health authorities, and the pharmaceutical industry?
About the HARMONY Alliance
HARMONY is a public-private European Network of Excellence for Big Data in Hematology, established in January 2017. Its mission is to unlock and spread valuable knowledge on hematologic malignancies (blood cancers) among a large number of stakeholders, with the goal to harness and mine Big Data to speed up the development of improved treatments for patients and more effective treatment strategies.
HARMONY currently has 53 Partners and 35 Associated Members from 22 countries and it is funded through the Innovative Medicines Initiative (IMI), Europe’s largest public-private initiative aiming to speed up the development of better and safer medicines for patients.
HARMONY has received funding from IMI 2 Joint Undertaking and is listed under grant agreement No.116026. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
Find more information about HARMONY in the video below and here.